JSES International 8 (2024) 141-146

Contents lists available at ScienceDirect

JSES International

journal homepage: www.jsesinternational.org

Components of metabolic syndrome as significant risk factors for postoperative complications following total shoulder arthroplasty: hypertension, diabetes, and obesity



Richelle Fassler, BA^a, Kenny Ling, MD^b, Jane Burgan, BS^a, David E. Komatsu, PhD^b, Edward D. Wang, MD^{b,*}

^aRenaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA ^bDepartment of Orthopaedics, Stony Brook University, Stony Brook, NY, USA

A R T I C L E I N F O

Keywords: Total shoulder arthroplasty Diabetes mellitus Hypertension Obesity Cardiovascular disease Renal failure

Level of evidence: Level III; Retrospective Cohort Comparison Using Large Database; Prognosis Study **Background:** Metabolic syndrome (MetS) is a known risk factor for adverse postoperative outcomes. However, the literature surrounding the effects of MetS on orthopedic surgery outcomes following total shoulder arthroplasty (TSA) remains understudied. The purpose of this study is to investigate the effect of MetS on postoperative 30-day adverse outcomes following TSA.

Methods: The American College of Surgeons National Surgical Quality Improvement Program database was queried for all patients who underwent TSA between 2015 and 2020. After exclusion criteria, patients were divided into MetS and no MetS cohorts. MetS patients were defined as presence of hypertension, diabetes, and body mass index > 30 kg/m². Bivariate logistic regression was used to compare patient demographics, comorbidities, and complications. Multivariate logistic regression, adjusted for all significant patient demographics and comorbidities, was used to identify the complications independently associated with MetS.

Results: A total of 26,613 patients remained after exclusion criteria, with 23,717 (89.1%) in the no MetS cohort and 2896 (10.9%) in the MetS cohort. On multivariate analysis, MetS was found to be an independent predictor of postoperative pneumonia (odds ratio [OR] 1.61, 95% confidence interval [CI] 1.02-2.55; P = .042), renal insufficiency (OR 4.09, 95% CI 1.67-10.00; P = .002), acute renal failure (OR 4.17, 95% CI 1.13-15.31; P = .032), myocardial infarction (OR 2.11, 95% CI 1.21-3.69; P = .009), nonhome discharge (OR 1.41, 95% CI 1.24-1.60; P < .001), and prolonged hospital stay > 3 days (OR 1.44, 95% CI 1.25-1.66; P < .001).

Conclusion: MetS was identified as an independent risk factor for postoperative pneumonia, renal insufficiency, acute renal failure, myocardial infarction, nonhome discharge, and prolonged hospital stay following TSA. These findings encourage physicians to medically optimize MetS patients prior to surgery to limit adverse outcomes.

© 2023 The Authors. Published by Elsevier Inc. on behalf of American Shoulder and Elbow Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

Total shoulder arthroplasty (TSA) is an effective surgical procedure for multiple shoulder disorders, with the potential to improve pain, shoulder function, and overall wellbeing.²⁴ Indications for TSA include glenohumeral arthritis, rotator cuff tear, and proximal humerus fracture.²¹ Over the recent years, the incidence of TSA has rapidly increased, with a 103.7% rise in procedures between 2011 and 2017 and a predicted increase of 235.2% by 2025.²⁶

Similarly, the number of people with metabolic syndrome (MetS) has grown.²⁰ The global prevalence of MetS is 20%-25%, with 35% of all adults and 50% of adults aged more than 60 years in the United States having MetS.^{1,20} MetS is defined by the World Health Organization as a pathologic condition that places patients at risk for cardiovascular disease and type 2 diabetes mellitus due to the combination of insulin resistance, hypertension, central obesity, and hyperlipidemia.^{2,23} Patients typically have insulin resistance with at least 2 of these other additional risk factors to diagnose MetS. The presence of these health conditions arises from multiple factors, such as genetics, sedentary lifestyles, diet composition, and higher calorie intake compared to energy expenditure.²³

Institutional review board approval was not required for this study.

^{*}Corresponding author: Edward D. Wang, MD, Department of Orthopaedics, Stony Brook University Hospital, HSC T-18, Room 080, Stony Brook, NY 11794-8181, USA. *E-mail address:* Edward.Wang@stonybrookmedicine.edu (E.D. Wang).

https://doi.org/10.1016/j.jseint.2023.08.019

^{2666-6383/© 2023} The Authors. Published by Elsevier Inc. on behalf of American Shoulder and Elbow Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Previous literature has shown that MetS is associated with adverse outcomes following orthopedic surgeries, specifically following total hip arthroplasty (THA) and total knee arthroplasty (TKA).⁷ For these surgeries, MetS placed patients at greater risk for cardiovascular complications, endocrine dysfunction, urinary tract infections, surgical site infections (SSIs), thromboembolic events, and osteoarthritis.⁷ Additionally, prior research demonstrates that certain patient population groups face greater postoperative complications because MetS is disproportionately prevalent in racial minority groups, females undergoing TKA, and males undergoing THA.⁶ Due to TSA's faster rate of increase compared to THA and TKA, it is important to investigate the relationship between MetS and postoperative complications following TSA.²⁶

Given the increasing demand for TSA and the rising prevalence of MetS with the United States' aging population, it is important to understand how MetS impacts postoperative complications following TSA. The purpose of this study was to analyze the relationship between MetS and adverse postoperative outcomes following TSA.

Methods

The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database was queried for all patients who underwent TSA between 2015 and 2020. The data available through the NSQIP database are collected by trained surgical clinical reviewers and are obtained from more than 600 hospitals in the United States. The data are periodically audited to maintain its accuracy and validity. The ACS-NSQIP database is fully deidentified, therefore rendering this study exempt from approval by our University's Institutional Review Board.

Current Procedural Terminology code 23472 was used to identify patients who underwent both anatomic and reverse TSA between 2015 and 2020. Patients aged less than 18 years are automatically excluded from the database. Cases for TSA due to trauma were also excluded. Patient cases were additionally excluded for missing information in any of the following variables: height, weight, total operative time, discharge destination, American Society of Anesthesiologists (ASA) classification, length of hospital stay, and readmission status.

MetS was defined as the presence of the following 3 characteristics: body mass index (BMI) > 30 kg/m^2 , diabetes mellitus, and hypertension. Both noninsulin and insulin-dependent diabetic patients were included. Patients with hypertension included those requiring antihypertensive medication for chronic hypertension for > 2 weeks preoperatively.

Patient demographics collected in this study include age, gender, BMI, ASA classification, functional status, smoking status, and chronic steroid use. Patient comorbidities including diabetes, dyspnea, chronic obstructive pulmonary disease, ascites, congestive heart failure, hypertension, dialysis, disseminated cancer, open wound/wound infection, unintentional weight loss, and bleeding disorders were collected. Surgical characteristics including preoperative transfusion and total operative time were also collected.

Postoperative complications that occurred within 30 days of surgery included superficial SSI, deep SSI, organ/space SSI, wound dehiscence, deep vein thrombosis/thrombophlebitis, pulmonary embolism, stroke/cerebrovascular accident, pneumonia, renal insufficiency, acute renal failure, myocardial infarction, cardiac arrest, sepsis, septic shock, bleeding transfusions, failure to wean, reintubation, reoperation, and readmission. Discharge destination, home vs. nonhome, and prolonged hospital stay > 3 days were also included in this analysis.

A total of 27,050 patients who underwent TSA between 2015 and 2020 were included in this study. Cases were excluded as follows: 152 for missing height/weight, 227 for unknown functional status, 11 for unknown discharge destination, 29 for missing ASA classification, 16 for missing length of hospital stay, and 2 for missing readmission status. The remaining 26,613 patients were divided into cohorts, with 23,717 (89.1%) in the no MetS cohort and 2896 (10.9%) in the MetS cohort (Fig. 1).

All statistical analyses were completed using SPSS Software version 29.0 (IBM Corp., Armonk, NY, USA). Patient demographics and comorbidities were compared between cohorts using bivariate logistic regression analysis. Multivariate binomial logistic regression, adjusted for all significant demographics and comorbidities, was then used to identify the postoperative outcomes independently associated with MetS. Odds ratios (ORs) were reported for 95% confidence intervals (CIs). Significance was set to P < .05.

Results

Bivariate analysis was used to identify patient demographics and comorbidities significantly associated with MetS patients undergoing TSA, shown in Table I. The characteristics significantly associated with the MetS cohort were age < 65 years (P < .001), female gender (P = .017), ASA ≥ 3 (P < .001), dependent functional status (P < .001), current nonsmoker (P < .001), dyspnea on exertion (P = .048), dyspnea at rest (P < .001), chronic obstructive pulmonary disease (P < .001), congestive heart failure (P < .001), open wound/wound infection (P = .013), and bleeding disorders (P = .004). In contrast, patients with MetS were less likely to be aged ≥ 75 years (P < .001).

Bivariate analysis was also used to identify postoperative outcomes significantly associated with MetS, shown in Table II. The outcomes significantly associated with the MetS cohort were pneumonia (P = .003), renal insufficiency (P < .001), acute renal failure (P = .009), myocardial infarction (P < .001), sepsis (P = .018), bleeding transfusions (P = .027), reoperation (P = .012), readmission (P < .001), nonhome discharge (P < .001), and prolonged hospital stay > 3 days (P < .001).

Multivariate logistic regression, including all significant demographics and comorbidities, was used to identify which postoperative outcomes were independently associated with MetS, shown in Table III. MetS was found to be an independent predictor of pneumonia (OR 1.61, 95% CI 1.02-2.55; P = .042), renal insufficiency (OR 4.09, 95% CI 1.67-10.00; P = .002), acute renal failure (OR 4.17, 95% CI 1.13-15.31; P = .032), myocardial infarction (OR 2.11, 95% CI 1.21-3.69; P = .009), nonhome discharge (OR 1.41, 95% CI 1.24-1.60; P < .001), and prolonged hospital stay > 3 days (OR 1.44, 95% CI 1.25-1.66; P < .001).

Discussion

In our study, we investigated 30-day postoperative outcomes associated with MetS in patients undergoing TSA between 2015 and 2020 using a large national database. We followed the precedent set by other large database studies, defining MetS as having a BMI > 30, hypertension, and diabetes mellitus.^{5,11} After adjusting for significant demographics and comorbidities, we identified MetS to be an independent risk factor for pneumonia, renal insufficiency, acute renal failure, myocardial infarction, nonhome discharge, and prolonged length of stay following TSA.

The term MetS encompasses multiple characteristics, including insulin resistance, central obesity, hypertension, and dyslipidemia, that impact the overall health of an individual.⁷ Potential negative health outcomes associated with MetS include increased cardio-vascular and thromboembolic risk, endocrine dysfunction, and development of osteoarthritis.⁷ Furthermore, the presence of abdominal obesity has also been shown to significantly increase



Figure 1 Inclusion and exclusion criteria for no MetS and MetS cohorts. NSQIP, National Surgical Quality Improvement Program; TSA, total shoulder arthroplasty; ASA, American Society of Anesthesiologists.

risk of insulin resistance and diabetes.^{2,18} The mechanism of the many medical complications seen among MetS patients is overall complex and multifactorial. For example, it has been suggested that obesity and insulin resistance lead to oxidative stress that increases atherogenesis and fibrosis.²²

As rates of obesity continue to rise across the United States, the demand for orthopedic surgery is increasing.¹⁸ Along with these increasing obesity rates, MetS has also been on the rise. A study by Murphy et al reported overall increasing trends in MetS diagnosis, with a 257% increase from 2002 to 2011.²⁰ Moreover, MetS has been reported to affect up to 40% of adults, and the amount of individuals affected markedly increases with age.⁷ The management of this condition greatly contributes to increased hospital costs and potentially burdens the healthcare system. Previous studies have shown that obesity and diabetes as independent factors place patients at higher risks for poor postoperative outcomes such as readmission and pulmonary complications in orthopedic surgeries.^{9,14} Therefore, the adverse outcomes associated with MetS patients following orthopedic surgery is an important area of investigation to improve overall patient management and outcomes.

Prior research on MetS in TSA patients has been limited, but overall shows increased risk of complications following orthopedic surgery. A study by Murphy et al that looked at TSA patients from 2002-2011 found overall increasing trends of MetS patients undergoing TSA and reported MetS to be an independent risk factor for multiple medical and surgical complications.²⁰ Marigi et al reported rates of deep infection, joint instability, venous thrombosis, and pulmonary embolism to be significantly higher in the MetS group following TSA.¹⁷ However,

a study by Garcia et al on TSA patients from 2005-2013 did not find MetS to be an independent predictor of adverse postoperative outcomes.⁵ Therefore, along with the rise in TSA utilization, it is important to clarify this potential increased risk of the MetS patient population.

In our study, we identified MetS to be an independent risk factor for both renal insufficiency and acute renal failure following TSA. This is consistent with prior research on shoulder arthroplasty, as Murphy et al found acute renal failure to be a statistically significant outcome among MetS patients.²⁰ Moreover, BMI > 35 kg/m² can significantly increase risk of postoperative medical complications, including renal insufficiency and failure.⁸ Patients with MetS are more likely to be at increased risk of adverse renal outcomes, as the oxidative stress and inflammation associated with increased adipose tissue may lead to endothelial dysfunction and hypertension.²⁷ Additionally, increased perirenal fat can cause high intrarenal pressures and has been shown to be an independent predictor of kidney dysfunction.¹² Kidney dysfunction itself has also been shown to lead to postoperative complications following TSA, including postoperative anemia requiring transfusion, nonhome discharge, and hospital readmission.¹⁰

We also identified MetS to be an independent predictor of pneumonia following TSA. Adverse pulmonary outcomes in MetS patients have been inconsistently reported in prior studies.⁷ Interestingly, a study by Cichos et al found MetS to be associated with decreased odds of pulmonary outcomes, including pneumonia and pulmonary embolism following hip fractures.⁴ However, it is well known that insulin-resistant states, such as those seen in MetS, can cause immune dysregulation, which may increase a

R. Fassler, K. Ling, J. Burgan et al.

Table I

Patient demographics and comorbidities in patients with and without metabolic syndrome following TSA.

redNumberPercentNumberPercentAcc23.717100.05.2896100.05Acc1404.83.00140-54657427.737.4423.73.00140-54557427.73140323.73.00160-7170040.3512.03.001.00160-7170040.3512.03.001.00160-7170040.5512.23.021.00160-7170.0012.7453.650.000.00070.1413.14753.4812.2442.38.00170.1570.0053.752.48.50.000.00070.1413.14753.680.000.000.00070.1413.14753.680.000.000.00070.1413.14754.822.2114.03.3.03370.1412.70453.680.000.00070.1412.70453.680.000.00070.1412.70453.6812.24891.303.03370.1512.7853.78.001.002.000.00071.212.70453.78.001.000.000.00071.212.70453.78.001.000.000.00071.312.8554.682.75.001.000.00072.312.0554.78.21.71.001.001 <th>Characteristic</th> <th>No metabolic syn</th> <th>drome</th> <th colspan="2">Metabolic syndrome</th> <th>P value</th>	Characteristic	No metabolic syn	drome	Metabolic syndrome		P value
Terl 23/17 10.0.8 2896 10.0.8 18-39 4 0.022 140 4.82 .001 18-39 4 0.022 140 4.82 .001 27.7 17.0 10.08 17.0 40.77 2.77 .001 Conter 10.08 12.3 42.3 .001 .001 .001 Fernale 13.147 55.45 167.3 .788 .007 .		Number	Percent	Number	Percent	
Age 18/3940.0021/404.480.0030.4940-440.0732.0737.442.480.00140-440.0732.0737.442.513	Total	23,717	100.0%	2896	100.0%	
B-3940.0021404.340.001B-574270030.85124024.06	Age				4.004	
ab-sh controlab sh control2.1.84.4.04.4.02.1.82.0.102.0.10control0.070.000.	18-39	4	0.02%	140	4.8%	.001
b.7.191/040.3%14.040.0%001conder70020.1%20.1%001Formale13.4055.4%167.357.8%0Male10.5046.6%122342.2%00110.313.4055.4%127.342.3%013.1-3435.7823.5%12.2%42.3%-5615.3.13928512.2%48.113.8%.5553.5-3.4928.5%12.2%42.143.7%.5553.5-3.4928.5%12.2%42.11.4.5%.5553.6%12.5%42.11.5.5%.555.566.5552.4%2.4.5%2.789.6.6%.555.566.5553.312.25645.2%2.0%.556.555.566.55513.312.25610.5%2.78%9.6.6%.578.566.578.578.56615.6%10.5%10.5%2.78%9.6.6%.578 <td>40-64</td> <td>6574</td> <td>27.7%</td> <td>744</td> <td>25.7%</td> <td><.001</td>	40-64	6574	27.7%	744	25.7%	<.001
Control1.001.001.001.011.011.011.011.01Fernale1.057044.681.0237.881.02Body mass index (kg/m)150.83800.000%1.0001.83.3012.743.5800.000%1.0001.83.3012.743.5800.000%1.00035.392.8951.2281912.038.0552.402.8951.2281912.038.0552.411.454.687.98.414.551.21.21.45.066.066.0661.21.2805.422.75.060.066Dependent2.1018.9482.051.060.065Dependent2.12018.9482.063.0205.070Dependent2.12018.9482.063.0205.0005Dependent1.8031.939.93.0308.0205.0005Dependent2.12018.9482.091.037.0005.0005Dependent2.12018.9482.091.037.0005.0005Dependent2.12018.9482.091.037.0005.0005Dependent1.8039.93.0005.0005.0005.0005Dependent1.8039.93.0005.0005.0005.0005Dependent1.8039.93.0005.0005.0005.0005Dependent1.80	5-74 >75	9703	40.9%	1420	49.0%	- < 001
mail Male13.1475.44.107357.38.20Male12.57044.6812.2342.2842.88Boly mass index (kg/m²)11.2.70453.6800.00023.18.51.570.581.2.8812.2142.336.555.553.2.002.04.853.6812.2842.1342.336.555.553.2.002.04.82.6842.142.356.555.555.553.2.001.2.5842.8342.142.354.555.755.555.755.555.755.555.755.555.755.555.755.555.755.555.755.555.755.755.555.755.755.755.755.755.755.755.755.755.755.757.755.757.755.757.755.757.755.757.755.757.755.757.7	≥75 Cender	7500	50.8%	728	23.1%	<.001
Mac Body max index (spm)105.7044.68122342.28>185.501550.83%00.00%1.00030.1349387824.4817.2442.3%6.5635.3392052.288.6130.846.5635.3392056.85702.696.6521.2321.286.81722.696.671-223.686.82214.556.6723.312.85054.2824.7555.586.6721.4302.5054.282.783.667.0011-22.53610.682.663.777.011-22.12018.64%2.632.067.0011.01012.120110.682.663.777.371.021110.682.663.777.377.371.021110.682.663.777.377.371.021110.682.663.577.377.371.031114.246.182.609.007.001.03114.246.182.609.007.001.03114.246.182.609.007.0011.03114.246.182.609.007.0011.03114.246.182.609.007.0011.03114.246.182.609.007.0011.03114.246.182.609.007.0011.03112.999.007.0<	Female	13 147	55.4%	1673	57.8%	.017
Body mass index (kg/m ²) Late Late Late Late Late Late 1-18.5 185 0.83% 0 0.00% 1.000 18.5-3.00 12.704 53.6% 0 0.03% 5.6% 3-34.30 2605 12.2% Api 0.03% 5.6% 3-43.00 2605 12.2% Api 0.03% 5.6% 3-43.00 2605 24.7% 8.5% 4.1 4.45% -600 1-4 1.6% 26.9% 27.9% 9.6% -000 -000% -00	Male	10,570	44.6%	1223	42.2%	
is is the set of the set o	Body mass index (kg/m^2)	,				
18.5.50012.70453.6800.00%-301-34.9289512.2889130.83.9553-30.9289512.2889130.83.955AA.fastifation805AA.fastifation12.80861.218.8512312.80861.201.85.33.85.351ndependent12.80861.966.87.85.35.85.35Pendent12.80.861.87.2663.92.03.806.87.800Dependent12.80.861.87.2663.92.03.800.87.800.87.800.87Dabete801.87.800.	>18.5	195	0.83%	0	0.00%	1.000
30.1-34.9SP7824.8%1.244.2.3%.9.553-3.9920458.6%7.812.6.3%.9.553-4020458.6%7.812.6.3%.9.553-54 chasification1.2.8674.5.8%2.4.75.8.55%.8.6.0.00%1-21.2.8674.5.8%2.4.75.8.55%.8.6.0.00% <td>18.5-30.0</td> <td>12,704</td> <td>53.6%</td> <td>0</td> <td>0.00%</td> <td>_</td>	18.5-30.0	12,704	53.6%	0	0.00%	_
3>39.9280512289130.8550.55AA castfaction	30.1-34.9	5878	24.8%	1224	42.3%	.956
≥4020458.6878126.939.55	35-39.9	2895	12.2%	891	30.8%	.955
AAA cashication	≥ 40	2045	8.6%	781	26.9%	.955
1-210,86745.8%42114.5%Functional status	ASA classification					<.001
2 3L8.902.472.478.5.2	1-2	10,867	45.8%	421	14.5%	
PunctionsJacks	≥ 3	12,850	54.2%	2475	85.5%	001
Interpriterin25.4%36.0%2.1%9.0%3.4%3.4%3.4%3.4%3.4%Current:1.20180.4%2633.0% <td< td=""><td>Functional status</td><td>22.249</td><td>08.0%</td><td>2708</td><td>06.6%</td><td><.001</td></td<>	Functional status	22.249	08.0%	2708	06.6%	<.001
non-over the set of the set	Dependent	25,248	1 0%	08	3 4%	
No. 1 2001 894% 263 8.0% 4 Ver 2516 10.6% 233 8.0% - Dabeters 2160 10.6% 233 8.0% - No 1.803 1.9% 0 0.0% - Noninsulin 1442 6.1% 1978 68.3% .9376 Dyspend 22.226 92.7% 2592 8.5% - No 22.226 92.7% 2592 8.5% - Moderate exertion 1424 6.0% 290 10.0% <.001	Current smoker	405	1.5%	58	5.4%	< 001
Yes251610.6%2338.0%Dabetes1.80391.9%00.0%-Noninsulin1.4426.1%1.9786.8.3%.9371Insulin4721.9%91.8%31.7%.936Dyspnea71.9%92.8.9.5%.9.5%Noninsulin14246.0%.292080.5%-Moderate exertion14246.0%.292090.0%.00%Art ret670.3%1.40.5%.0488COPD15256.4%2.669.5%.000%No2.19293.6%2.609.15%.000%Yes15256.4%2.669.5%.000%Yes15256.4%2.669.5%.000%Yes1360.6%.000%.000%.000%Yes1360.6%.000%.000%.000%Yes14/2962.4%2.869.9.7%.000%No23.5819.9.5%2.869.9.7%.000%Yes1360.6%.000%.000%.000%Yes1360.6%.000%.000%.000%Yes1360.6%.000%.000%.000%Yes1360.6%.000%.000%.000%Yes1360.97%2.869.9.7%.000%No2.36499.97%2.869.9.7%.000%Yes3.6409.97%2.869.9.6%	No	21 201	89.4%	2663	92.0%	<.001
platersConstructionConstructionConstructionConstructionNo21,80391,91500.0%-Nominsulin14426.1%197868.3%.9376jinsulin14246.0%299181.7%.9366Dyspine936.000%.000%.000%Ari rest670.3%140.5%.0681COPO000%.000%.000%Ves15256.4%246.85%.0000%Ves15256.4%246.000%.000%Ves15256.4%246.000%.000%Ves123,71399.9%2896100.0.0%.000%Ves123,51199.9%28960.000%.000%CHF000%.000%.000%Ves1360.6%411.4%.028No23,64199.7%2866.99.7%.000%Ves13.64099.7%2868.99.9%.000%Ves13.64099.7%2876.99.9%.000%No23,64399.8%289299.9%.000%Ves13.64099.7%2876.99.8%.000%No23,64399.8%2890.98.8%.02%No23,64399.8%2890.99.8%.02%No23,64399.8%2890.99.8%.02%No23,64399.8% <td>Yes</td> <td>2516</td> <td>10.6%</td> <td>233</td> <td>8.0%</td> <td></td>	Yes	2516	10.6%	233	8.0%	
No144219%00.0%Noninsulin4721.9%197886.3%39.37Insulin4721.9%197831.7%39.68Dyspnea31.7%39.68DyspneaModerate exertion14246.0%20.980.5%-Ar rest670.3%140.0%-40.88COPNo21.9236.5%265091.5%Yes1526.4%265090.0%No23.71399.9%2896100.0%Yes40.0%No23.5199.4%285588.6%No13.76%00.0%No13.76%00.0%No13.76%0.8%289690.7%No13.6199.7%288699.7%No13.6199.7%288699.7% <td>Diabetes</td> <td>2010</td> <td>10,0,0</td> <td>200</td> <td></td> <td></td>	Diabetes	2010	10,0,0	200		
Nonsulin1426.1%19786.8.3%9.97Jusuin4721.989.183.1.7%9.86Dyspena5.928.95%-Moderate exercion14246.0%2.9010.0%<.001	No	21,803	91.9%	0	0.0%	_
<table-container>Insulin4721.9%9.1%<th< td=""><td>Noninsulin</td><td>1442</td><td>6.1%</td><td>1978</td><td>68.3%</td><td>.937</td></th<></table-container>	Noninsulin	1442	6.1%	1978	68.3%	.937
DyspineANo22,22693,7X259289,5X,Moderate exertion14246,0X29010,0X,,001Ar rest0.3X140.5X,,,001No22,19293,6X265091,5X,,,	Insulin	472	1.9%	918	31.7%	.936
No22.2693.7%250289.5%-Moderate exertion14246.0%29010.0%<.001Ar rest.0.3%1.40.5%0.08COPD	Dyspnea					
Moderate exertion14246.0%29010.0%<.000Ar rest670.3%140.5%.048COP2.19293.6%26091.5%.001Yes15256.4%26685.5%.000No2.19293.6%26000.0%.000Yes3.71399.9%2896100.0%.000Yes3.71399.9%2896100.0%.000Yes3.58199.4%285598.6%.000Yes1360.6%411.4%.016No892137.6%00.0%.000Yes1360.6%411.4%.016No3.64199.7%286699.7%.010Yes760.3%100.3%.016No23.65999.8%282699.8%.016Yes770.3%18.068.016No23.66899.8%28099.8%.016Yes23.66899.8%28099.8%.016No23.65999.8%28099.6%.016Yes23.55695.5%.028.028.028No23.56499.8%268695.5%.016No23.65695.1%.76995.6%.016Yes16149.9%.76995.6%.016Yes25.5695.5%.028.016.055Yes16	No	22,226	93.7%	2592	89.5%	-
Arest670.3%140.5%0.0%COPD	Moderate exertion	1424	6.0%	290	10.0%	<.001
COP COP COP COP No 22,192 93,6% 2650 91,5% 4 Yes 1525 6.6% 2650 91,5% 4 Ascites	At rest	67	0.3%	14	0.5%	.048
No21,19293.6%265091.5%Yes15256.4%2468.5%Ascites23,71399.9%29.6%100.0%Yes40.02%00.0%Yes40.02%00.0%CHF $<$.0010.0%0Yes13.6%0.0%00.0%Yes13.6%0.0%0.0%0Yes13.6%0.0%0.0%0Yes14.7966.24%2856100.0%Yes14.7966.24%2896100.0%Yes14.7960.23%00.3%Yes14.7960.23%100.3%Yes23.65999.8%289299.9%Yes23.65999.8%289299.9%Yes700.3%160.6%Yes700.3%160.6%Yes700.3%287899.4%Yes700.3%289099.8%Yes740.2%60.2%No23.65699.8%289096.7%Yes742.4%963.3%Yes5742.4%963.3%Yes1614.9%2.66995.6%Yes1614.9%2.66995.6%Yes1614.9%1.6%3.3%Yes1614.9%1.6%3.3%Yes1614.9%1.6%3.3% <t< td=""><td>COPD</td><td>22,102</td><td>02.6%</td><td>2650</td><td>01 5%</td><td><.001</td></t<>	COPD	22,102	02.6%	2650	01 5%	<.001
Its 15.3 0.4% 240 6.3% 999 No 23,713 99.9% 2896 100.0%	No	22,192	93.6%	2650	91.5%	
No 23,713 99,9% 2896 100,0% Yes 4 0.02% 0 0.0% Yes 4 0.02% 0 0.0% No 23,581 99,4% 2855 98,6% 4 No 23,581 99,4% 2855 98,6% 4 Hypertension	Ascites	1525	0.4%	240	8.3%	000
No15.1516.1710.02%10.00%10.00%CHF <t< td=""><td>No</td><td>23 713</td><td>99 9%</td><td>2896</td><td>100.0%</td><td>.555</td></t<>	No	23 713	99 9%	2896	100.0%	.555
CH	Yes	4	0.02%	0	0.0%	
No23,58199.4%285598.6%Yes1360.6%1.1	CHF	-		-		<.001
<table-container>Yes160.6%411.4%Hypertension</table-container>	No	23,581	99.4%	2855	98.6%	
Hypertension	Yes	136	0.6%	41	1.4%	
No 821 37.6% 0 0.0% Yes 14,796 62.4% 2896 100.0% On dialysis	Hypertension					.963
Yes 14,796 6.24 2296 100.000 On dialysis 23,641 99.7% 2886 99.7% .82 Yes 76 0.33 10 0.33	No	8921	37.6%	0	0.0%	
On dialysis	Yes	14,796	62.4%	2896	100.0%	
No23,64199.7k288b99.7kYes769.3%100.3%Disseminated cancer	On dialysis	22 6 41	00.7%	2000	00.7%	.824
res760.3 k100.3 kDisseminated cancer	No	23,641	99.7%	2886	99.7%	
No23,65999.8%289299.9%260Yes580.2%40.1%Open wound/wound infection	Tes Disseminated cancer	70	0.3%	10	0.3%	260
No1001000100010001000Open wound/wound infection	No	23 659	99.8%	2892	99 9%	.203
Open wound/wound infection	Yes	58	0.2%	4	0.1%	
No23,64099,7%287899,4%Yes770.3%180.6%10% weight loss23,66899.8%289099.8%No23,66899.8%289099.8%Yes490.2%60.2%Bleeding disorders	Open wound/wound infection	50	0.270	•	0110	.013
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	No	23,640	99.7%	2878	99.4%	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Yes	77	0.3%	18	0.6%	
No23,66899.8%289099.8%Yes490.2%60.2%Bleeding disorders	10% weight loss					.995
Yes49 0.2% 6 0.2% Bleeding disorders	No	23,668	99.8%	2890	99.8%	
Bleeding disorders	Yes	49	0.2%	6	0.2%	
No23,14397.6%280096.7%Yes5742.4%963.3%Chronic steroid use	Bleeding disorders					.004
Yes5742.4%963.3%Chronic steroid use	No	23,143	97.6%	2800	96.7%	
No 22,556 95.1% 2769 95.6% Yes 1161 4.9% 127 4.4% Preoperative transfusion	Yes	574	2.4%	96	3.3%	222
No $22,536$ 95.1% 2769 95.6% Yes1161 4.9% 127 4.4% Preoperative transfusion	Chronic steroid use	22 550	05.1%	2760		.228
resresresresresresProperative transfusion $23,670$ 99.8% 2886 99.5% Yes 47 0.2% 10 0.5% Total operative time -79 6072 25.6% 710 24.5% $.574$ $80-128$ $11,800$ 49.8% 1418 49.0% $ \geq 129$ 5845 24.6% 768 26.5% $.060$	No	22,556	95.1%	2769	95.6%	
No 23,670 99.8% 2886 99.5% Yes 47 0.2% 10 0.5% Total operative time - 0-79 6072 25.6% 710 24.5% .574 80-128 11,800 49.8% 1418 49.0% - ≥129 5845 24.6% 768 26.5% .060	Preoperative transfusion	1101	4.5%	127	4.4%	11
Yes 47 0.2% 10 0.5% Total operative time -79 6072 25.6% 710 24.5% .574 80-128 11,800 49.8% 1418 49.0% - ≥129 5845 24.6% 768 26.5% .060	No	23 670	99.8%	2886	99 5%	.11
Total operative time 6072 25.6% 710 24.5% .574 0-79 6072 25.6% 710 24.5% .574 80-128 11,800 49.8% 1418 49.0% - ≥129 5845 24.6% 768 26.5% .060	Yes	47	0.2%	10	0.5%	
0-79607225.6%71024.5%.57480-12811,80049.8%141849.0%-≥129584524.6%76826.5%.060	Total operative time			-		
80-128 11,800 49.8% 1418 49.0% - ≥129 5845 24.6% 768 26.5% .060	0-79	6072	25.6%	710	24.5%	.574
≥129 5845 24.6% 768 26.5% .060	80-128	11,800	49.8%	1418	49.0%	_
	≥129	5845	24.6%	768	26.5%	.060

TSA, total shoulder arthroplasty; ASA, American Society of Anesthesiologists; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure. Bold P value indicates statistical significance with P value set to <.05.

R. Fassler, K. Ling, J. Burgan et al.

Table II

Thirty-day postoperative outcomes in patients with and without metabolic syndrome.

Postoperative complication	No metabolic syn	drome	Metabolic syndrome		P value
	Number	Percent	Number	Percent	
Superficial SSI	60	0.25%	9	0.31%	.564
Deep SSI	14	0.06%	3	0.10%	.377
Organ space SSI	55	0.23%	3	0.10%	.174
Wound dehiscence	16	0.07%	1	0.03%	.516
DVT/Thrombophlebitis	74	0.31%	9	0.31%	.991
Pulmonary embolism	65	0.27%	9	0.31%	.723
Stroke/CVA	19	0.08%	3	0.10%	.679
Pneumonia	101	0.43%	24	0.83%	.003
Renal insufficiency	15	0.06%	8	0.28%	<.001
Acute renal failure	6	0.03%	4	0.14%	.009
Myocardial infarction	55	0.23%	17	0.59%	<.001
Cardiac arrest	12	0.05%	2	0.07%	.684
Sepsis	30	0.13%	9	0.31%	.018
Septic shock	12	0.05%	1	0.03%	.714
Bleeding transfusions	404	1.70%	66	2.28%	.027
Failure to wean	26	0.11%	0	0.00%	.998
Reintubation	39	0.16%	9	0.31%	.085
Reoperation	313	1.32%	55	1.90%	.012
Readmission	662	2.79%	113	3.90%	<.001
Mortality	36	0.15%	6	0.21%	.480
Nonhome discharge	1892	7.98%	377	13.02%	<.001
Prolonged hospital stay (>3 days)	1386	5.84%	295	10.19%	<.001

SSI, surgical site infection; DVT, deep vein thrombosis; CVA, cerebrovascular accident.

Bold *P* value indicates statistical significance with *P* value set to <.05.

Table III

Multivariate analysis of 30-day postoperative outcomes in patients with and without metabolic syndrome following TSA, adjusted for significant demographics and comorbidities.

Postoperative complication	Odds ratio	95% CI	P value
Pneumonia	1.61	1.02-2.55	.042
Renal insufficiency	4.09	1.67-10.00	.002
Acute renal failure	4.17	1.13-15.31	.032
Myocardial infarction	2.11	1.21-3.69	.009
Sepsis	1.74	0.80-3.78	.159
Bleeding transfusions	1.11	0.85-1.46	.438
Reoperation	1.28	0.95-1.72	.109
Readmission	1.19	0.97-1.47	.098
Nonhome discharge	1.41	1.24-1.60	<.001
Prolonged hospital stay > 3 days	1.44	1.25-1.66	<.001

TSA, total shoulder arthroplasty: CI, confidence interval.

Bold *P* value indicates statistical significance with *P* value set to <.05.

patient's likelihood of infectious complications.³ Furthermore, immune dysregulation may impact leukocyte counts, and preoperative leukocytosis has been identified as an independent predictor of additional postoperative complications following TSA, such as bleeding transfusions and nonhome discharge.¹³

MetS is a well-known risk factor for cardiovascular disease, and increased risk of postoperative myocardial infarction and other adverse cardiovascular events have previously been reported.^{4,7,20} Similarly, we identified MetS to be an independent predictor for postoperative myocardial infarction. Cardiovascular disease is a common comorbidity among obese individuals and has been found to be twice as likely among MetS patients.^{2,18} The chronic inflammation in MetS has been suggested to lead to this increased prevalence due to endothelial cell dysfunction and activation of monocytes.²² Of note, patients with MetS are at increased risk of death from cardiovascular disease compared to the general population.²⁵ Furthermore, having a greater number of MetS characteristics has been associated with increased risk of adverse cardiovascular outcomes, and the stress of surgery could further exacerbate these risk factors.⁷

Finally, we identified MetS to be an independent risk factor for prolonged hospital stay and nonhome discharge. This finding is similar to prior studies on MetS patients undergoing TSA.²⁰ A study by Mahure et al reported that patients with diabetes, a component of MetS, are at increased risk of nonhome discharge and prolonged length of stay following elective TSA.¹⁶ Nonhome discharge and longer length of stay among diabetic patients have both been shown to lead to increased hospital costs, decreased bone strength, and impaired return to independent functional status.^{14,15} Therefore, the negative impact of MetS on these outcomes may be important to consider to minimize both hospital costs and negative long-term patient outcomes.

Our study is limited to the information available on the ACS-NSQIP database. Therefore, we are not able to analyze outcomes outside of a 30-day postoperative window. Furthermore, the broad categorical format of the NSQIP database restricted our ability to analyze other potential contributing factors including severity of each comorbidity, specific indications for surgery, and individual physician skill. Additionally, our definition of MetS was limited to the characteristics available through the NSQIP database, with factors such as abdominal waist circumference and hyperlipidemia unable to be assessed. Additionally, socioeconomic status and educational level, identified in prior studies to affect the development of MetS, were unable to be investigated.¹⁹ Further research should be directed at better understanding how the management of individual MetS components could improve outcomes.²⁸ Overall, we were able to use a large national database to investigate the postoperative outcomes associated with MetS following TSA. This contributes to upper extremity literature regarding the postoperative outcomes in MetS patients.

Conclusion

MetS was identified as an independent predictor of postoperative pneumonia, renal insufficiency, acute renal failure, myocardial infarction, nonhome discharge, and prolonged hospital stay > 3 days within 30 days following TSA. As the demand for TSA continues to rise, along with the increase in obesity and MetS patients, it is important to understand the risk factors and outcomes in this patient population to minimize adverse outcomes

Disclaimers:

Funding: No funding was disclosed by the authors.

Conflicts of interest: The authors, their immediate families, and any research foundation with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. Patient consent: Obtained.

References

- 1. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 2015;313:1973-4. https:// doi org/10 1001/jama 2015 4260
- 2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes Federation Task Force on epidemiology and Prevention; national heart, Lung, and Blood Institute; American heart association: World heart Federation; International Atherosclerosis Society; and International association for the study of obesity. Circulation 2009;120:1640-5. https://doi.org/ 10.1161/circulationaha.109.192644
- 3. Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on Immunity. Adv Nutr 2016;7:66-75. https://doi.org/10.3945/ an 115 010207
- 4. Cichos KH, Churchill JL, Phillips SG, Watson SL, McGwin G Jr, Ghanem ES, et al. Metabolic syndrome and hip fracture: epidemiology and perioperative outcomes. Injury 2018;49:2036-41. https://doi.org/10.1016/j.injury.2018.09.012. 5. Garcia GH, Fu MC, Webb ML, Dines DM, Craig EV, Gulotta LV. Effect of metabolic
- syndrome and obesity on complications after shoulder arthroplasty. Orthopedics 2016;39:309-16. https://doi.org/10.3928/01477447-20160517-03.
- Gonzalez Della Valle A, Chiu YL, Ma Y, Mazumdar M, Memtsoudis SG. The metabolic syndrome in patients undergoing knee and hip arthroplasty: trends and in-hospital outcomes in the United States. J Arthroplasty 2012;27:1743-1749.e1. https://doi.org/10.1016/j.arth.2012.04.011
- 7. Guofeng C, Chen Y, Rong W, Ruiyu L, Kunzheng W. Patients with metabolic syndrome have a greater rate of complications after arthroplasty: a systematic review and meta-analysis. Bone Joint Res 2020;9:120-9. https://doi.org/ 10.1302/2046-3758.93.Bir-2019-0138.R1
- 8. Gupta AK, Chalmers PN, Rahman Z, Bruce B, Harris JD, McCormick F, et al. Reverse total shoulder arthroplasty in patients of varying body mass index. J Shoulder Elbow Surg 2014;23:35-42. https://doi.org/10.1016/j.jse.2013.07.043.
- 9. Kashanchi K, Nazemi A, Komatsu D, Wang E. Level of obesity is directly associated with complications following Arthroscopic rotator cuff Repair. J Shoulder Elbow Surg 2020;30:1581-7. https://doi.org/10.1016/j.jse.2020.09.029.
- Kim M, Capotosto S, Nazemi A, Tantone R, Wang E, Ling K, et al. Kidney 10. dysfunction is a significant risk factor for 30-day postoperative complications following shoulder arthroplasty. Semin Arthroplasty JSES 2022;32:623-32. https://doi.org/10.1053/j.sart.2022.04.007
- 11. Kotzur T, Singh A, Vivancos Koopman I, Armstrong C, Brady N, Moore C. The impact of metabolic syndrome and obesity on perioperative total joint arthroplasty outcomes: the obesity Paradox and risk Assessment in total joint

arthroplasty. Arthroplast Today 2023;21:101139. https://doi.org/10.1016/ i artd 2023 101139

- 12. Lamacchia O, Nicastro V, Camarchio D, Valente U, Grisorio R, Gesualdo L, et al. Paraand perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients. Nephrol Dial Transplant 2011;26:892-8. https://doi.org/10.1093/ndt/gfq522.
- 13. Ling K, Tsouris N, Kim M, Smolev E, Komatsu D, Wang E. Abnormal preoperative leukocyte counts and postoperative complications following total shoulder arthroplasty. JSES Int 2023;7:601-6. https://doi.org/10.1016/ j.jseint.2023.03.001.
- 14. Lung BE, Bisogno M, Kanijva S, Komatsu DE, Wang ED, Early postoperative complications and discharge time in diabetic patients undergoing total shoulder arthroplasty. J Orthop Surg Res 2019;14:9. https://doi.org/10.1186/ \$13018-018-1051-3
- 15. Macey LR, Kana SM, Jingushi S, Terek RM, Borretos J, Bolander ME. Defects of early fracture-healing in experimental diabetes. I Bone Joint Surg Am 1989:71: 722-33
- 16. Mahure S, Mollon B, Quien M, Karia R, Zuckerman J, Kwon Y. Impact of diabetes on perioperative complications in patients undergoing elective total shoulder arthroplasty. Bull Hosp Jt Dis (2013) 2017;75:173-9.
- 17. Marigi E, Marigi I, Crowe MM, Ortiguera CJ, Ledford CK, Werthel JD, et al. Primary reverse shoulder arthroplasty in patients with metabolic syndrome is associated with increased rates of deep infection. J Shoulder Elbow Surg 2021;30:2032-40. https://doi.org/10.1016/j.jse.2020.12.025. 18. Monroe EJ, Hardy R, Holmquist J, Brand JC. Obesity and reverse total shoulder
- arthroplasty. Curr Rev Musculoskelet Med 2022;15:180-6. https://doi.org/ 10 1007/s12178-022-09753-8
- 19. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by Race/Ethnicity and Sex in the United States, national health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis 2017;14:E24. https:// doi.org/10.5888/pcd14.160287.
- 20. Murphy AB, Menendez ME, Watson SL, Ponce BA. Metabolic syndrome and shoulder arthroplasty: epidemiology and peri-operative outcomes. Int Orthop 2016;40:1927-33. https://doi.org/10.1007/s00264-016-3214-3
- 21. Rabinowitz J, Kothandaraman V, Lin J, Li X, Friedman RJ, Eichinger JK. Utilization of shoulder arthroplasty in the United States – an analysis of current trends and future predictions. Semin Arthroplasty JSES 2020;30:200-9. https:// doi org/10 1053/i sart 2020 08 004
- 22. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Ādv Cardiovasc Dis 2017;11:215-25. https://doi.org/10.1177/ 1753944717711379
- 23. Saklayen MG. The global Epidemic of the metabolic syndrome. Curr Hypertens Rep 2018;20:12. https://doi.org/10.1007/s11906-018-0812-
- 24. Schwartz BE, Savin DD, Youderian AR, Mossad D, Goldberg BA. National trends and perioperative outcomes in primary and revision total shoulder arthroplasty: trends in total shoulder arthroplasty. Int Orthop 2015;39:271-6. https:// doi.org/10.1007/s00264-014-2614-5.
- 25. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Risk factor and Life Expectancy research group. Am J Epidemiol 1998;148:958-66.
- 26. Wagner ER, Farley KX, Higgins I, Wilson JM, Daly CA, Gottschalk MB. The incidence of shoulder arthroplasty: rise and future projections compared with hip and knee arthroplasty. J Shoulder Elbow Surg 2020;29:2601-9. https:// doi.org/10.1016/j.jse.2020.03.049
- 27. Zhang X, Lerman LO. The metabolic syndrome and chronic kidney disease. Transl Res 2017;183:14-25. https://doi.org/10.1016/j.trsl.2016.12.004
- Zmistowski B, Dizdarevic I, Jacovides CL, Radcliff KE, Mraovic B, Parvizi J. Patients with uncontrolled components of metabolic syndrome have increased risk of complications following total joint arthroplasty. J Arthroplasty 2013;28: 904-7. https://doi.org/10.1016/j.arth.2012.12.018.